“This study aims to optimize the amount of chemotherapy that patients with HER2-positive breast cancer receive. By giving one chemotherapy drug in combination with anti-HER2 antibodies before surgery, a combination known to be extremely effective, physicians can personalize the amount of therapy needed after surgery. If no cancer remains at surgery, patients will not receive any further chemotherapy, and thus be spared unnecessary toxicity. The trial will evaluate the safety and efficacy of this approach for the patients who have a complete response to this limited chemotherapy.”

-Nadine M. Tung, M.D.